Datroway filed for TNBC in EU after data delay Daiichi Sankyo and AstraZeneca have moved swiftly to file for approval of TROP2-targeting Datroway for triple-negative breast cancer.

#DaiichiSankyo and #AstraZeneca have pressed swiftly to file for approval of their #TROP2-targeting drug Datroway for triple-negative #breastcancer (TNBC) in the #EU, shortly after reporting positive #survivaldata in a pivotal trial.

Arrive and survive forecasts based on:

#fertility
#longevity

#survivaldata from hunter-gatherer societies

#hindcasts from general circulation models

principles of #populationecology

#data
#keyintelligencequestions #KIQ
#archaeology #history #science #humanitiesmatters